Esperion shareholders approve 6.25M share increase to 2022 stock plan

Esperion Therapeutics, Inc.

Shareholders approved amendment to 2022 Stock Option and Incentive Plan, increasing authorized shares by 6,250,000.
Class III directors Jay P. Shepard (75.8M for) and Seth H.Z. Fischer (83.3M for) elected to board until 2028.
Advisory vote on executive compensation passed with 70.8M for, 26.7M against, 1.5M abstain.
Ratification of Ernst & Young as independent auditor for FY2025 approved: 118.2M for, 16.1M against.
Shares outstanding as of record date: 198,149,421; quorum of 136,468,661 shares present.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.